A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

PHASE3RecruitingINTERVENTIONAL

Enrollment

808

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

NSCLC

Interventions

DRUG

QL2107

200mg on day 1 of each 21-day cycle of the study

DRUG

Pemetrexed

500 mg/m2 on Day 1 of each 21-day cycle of the study

DRUG

Carboplatin

Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles

DRUG

Keytruda®

200mg on day 1 of each 21-day cycle of the study

Trial Locations (1)

RECRUITING

Shandong First Medical University Cancer Hospital, Jinan

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY